Omeros Corporation (OMER)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.1500 |
| Open | 3.1500 |
| Bid | 3.0500 x 800 |
| Ask | 3.3000 x 800 |
| Day's Range | 2.9900 - 3.1800 |
| 52 Week Range | 1.7400 - 7.7500 |
| Volume | |
| Avg. Volume | 563,049 |
| Market Cap | 193.836M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | 0.98 |
| EPS (TTM) | 3.1390 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for OMER
Related Research
- Omeros CorporationAnalyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.RatingFair ValueEconomic MoatyesterdayMorningstar
- Business Wire
Omeros Corporation Reports Third Quarter 2022 Financial Results
SEATTLE, November 09, 2022--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2022, which include:
- Business Wire
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
SEATTLE, November 08, 2022--Omeros Corporation (Nasdaq: OMER) today announced that the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has reached a decision on the company’s formal dispute resolution request appealing the issuance by FDA’s Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN) and the Division of Nonmalignant Hematology (the review division) of a complete response letter (CRL) concerning the biologics license application (BLA) for narsop
- Business Wire
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
SEATTLE, November 04, 2022--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022, on Wednesday, November 9, 2022, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
